Invest Now
Products +
Pricing
Trading & Investing +
Calculators +
Support +
Learn +
IPO +
Partner
About us +
#AndekhaSach New
Login Open an account
Samco securities limited
Samco Star Rating Ads

Bal Pharma Ltd Share Price

₹ 0 (%)

Updated on 01-01-1970 5:30 AM

Stock Rating

Pros 0

 

Cons 9

Bal Pharma Ltd Price Performance

  • Day's Low
  • ₹0
  • Day's High
  • ₹0
₹ 0
  • 52-w low
  • ₹0
  • 52-w high
  • ₹0
0
  • Day's open
    ₹0
  • Previous close
    ₹0
  • VWAP
    ₹0
  • Lower price band
    ₹0
  • Upper price band
    ₹0

Today's Market Action

Its last traded stock price on BSE was 121.05 up by 0.25%. The total volume of shares on NSE and BSE combined was 1,214 shares. Its total combined turnover was Rs 0.01 crores.

Bal Pharma Ltd Medium and Long Term Market Action

The stock price of Bal Pharma Ltd is down by -100% over the last one month. It is down by -100% over the last one year. Don't forget to check the full stock price history in the table below.

Bal Pharma Ltd Fundamentals

  • Market Cap (Cr): 192

  • Book Value (₹):

  • Stock P/E:

  • Revenue (Cr):

  • Total Debt (Cr):

  • Face Value (₹):

  • Roce (%):

  • ROE (%):

  • Earnings (Cr):

  • Promoter’s Holdings (%):

  • EPS (₹):

  • Debt to Equity:

  • Dividend Yield (%):

  • Cash (Cr):

Bal Pharma Ltd Mutual fund holdings and trends

FUND NAME Quantity Monthly Change (Qty)

Bal Pharma Ltd Shareholding Pattern

Similar Stocks

Company Price Market Cap (Cr) P/E

About Bal Pharma Ltd

Data not available.

Bal Pharma Ltd FAQ's

What is Share Price of Bal Pharma Ltd?

What is the Market Cap of Bal Pharma Ltd?

What is PE Ratio of Bal Pharma Ltd?

What is PB Ratio of Bal Pharma Ltd?

What is the CAGR of Bal Pharma Ltd?

How to Buy Bal Pharma Ltd Share?

Financials

(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)
(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

News

Review

Pros

  • No Data Available

Cons

  • Momentum Strength
    The stock is currently exhibiting weak momentum, & is showing weak relative strength.
  • Low Sustainable RoE
    The company's sustainable return on equity is lower than the expected cost of capital which implies that the underlying business will destruct value over a period of time due to it's inability to generate superior returns on capital.
  • Low Return on Capital Employed
    The company is unable to generate sufficient return on capital employed which impairs it's ability to generate high return for shareholders after accounting for taxes, interest and other non-equity stakeholders.
  • Low Interest Coverage
    The company has a very low Interest coverage ratio of 2.13 times which implies that a large portion of operating profits are getting attributed to payment of interest to debtholders. This leaves lower earnings and cash flows for equity shareholders which is negative for returns.
  • Highly Cyclical Industry
    The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
  • Low Pricing Power & High Competition
    The business has extremely low pricing power and is vulnerable to competitive pressure which can significantly impact shareholder returns.
  • High Debt
    The company has a very high debt to equity ratio of 2.25. Considering the fact that the business carries a high quantum of debt, equity shareholders shall carry higher risk in the business in case of an adverse interest rate cycle or downturn in economic cycle.
  • Poor Capital Allocation
    The company has disproportionately high amount of assets locked up in working capital, cash and cash equivalents, loans and advances, etc to the extent of 72.94 % of total assets. This reflects poorly on the capital allocation strategy of the management which negatively impacts shareholder returns.
  • Poor Working Capital Cycle
    The company has a very poor working capital cycle of 221 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.

Valuation Analysis

Margin of safety
(19/12/2024)
Stock Valuation
Green line
99
0.00%
0.00% People are bullish about Bal Pharma Ltd
100.00%
100.00 % People are bearish about Bal Pharma Ltd

What is your opinion about this Stock?

Historical Data

Samco Star Rating Ads

Bal Pharma Ltd

₹ 0 (%)

Brokerage & Taxes at Samco

Brokerage & Taxes at Other traditional broker

Potential Brokerage Savings with Samco ₹ 49.62()

Top Gainers (NIFTY 50)

Stock Name Change %

    Top Losers (NIFTY 50)

    Stock Name Change %

      ×

      Filing Complaints on SCORES

      Easy & quick Easy & quick

      1. Register on SCORES portal

      2. Mandatory details for filling complaints on SCORES

      Name | PAN | Address | Mobile | Number | E-mail ID

      3. Benefits

      Effective Communication

      Speedy redressal of the grievances

      Website Icon
      Open Free Account Now
      Open a Demat Account

      Free Trading & Demat Account

      +91